Table 4 Standardized incidence ratio (SIR) of specific cancer types among subjects in the biologics cohort and nonbiologic DMARDs cohort

Non-hematologic cancers

73

88.46

0.83 (0.65, 1.04)

455

347.47

1.31 (1.19, 1.44)

Oral cavity

2

4.55

0.44 (0.05, 1.59)

20

17.92

1.12 (0.68, 1.72)

Digestive system¹

20

32.03

0.62 (0.38, 0.97)

135

125.75

1.07 (0.90, 1.27)

Lungs²

11

10.39

1.06 (0.53, 1.89)

57

40.77

1.40 (1.06, 1.81)

Breast, cervix³

22

19.96

1.10 (0.69, 1.67)

115

78.45

1.47 (1.21, 1.76)

Bladder/kidney⁴

14

15.75

0.89 (0.49, 1.49)

96

61.81

1.55 (1.26, 1.90)

Melanoma

0

0.21

-

0

0.83

-

NMSC

5

2.43

2.05 (0.66, 4.79)

15

9.58

1.57 (0.88, 2.58)

Unspecified origin

4

5.79

0.69 (0.19, 1.77)

32

22.76

1.41 (0.96, 1.99)

Hematologic cancers ⁵

16

3.45

4.64 (2.65, 7.53)

31

13.57

2.28 (1.55, 3.24)

Lymphoma

13

2.12

6.13 (3.26, 10.49)

21

8.34

2.52 (1.56, 3.85)

NHL

12

2.05

5.86 (3.02, 10.24)

20

8.06

2.48 (1.52, 3.83)

HL

1

0.07

13.97 (0.18, 77.7)

1

0.28

3.56 (0.05, 19.79)

Leukemia

1

1.33

0.75 (0.01, 4.18)

9

5.23

1.72 (0.79, 3.27)